We are proud to share that TargED joins forces with Good Biomarker Sciences (GBS) to develop a biomarker assay that supports TargED lead compound, Microlyse towards and throughout clinical studies. The collaboration is supported with a MIT R&D grant from the Economic Board Utrecht and… Read More »TargED and GBS Leiden partner up and were granted MIT R&D
Again, we can share some thrilling news! TargED is awarded the @NWO Take Off II loan (€250.000) to further develop its clot-busting lead compound, Microlyse, which could ultimately help millions of patients around the globe. What a welcome reward to a remarkable year 2020! See… Read More »TargED is granted the NWO Take Off II loan
November 24th, 2020 – We are very proud to announce the closing of a €1.35m Seed investment from Curie Capital, Utrecht Health Seed Fund and Fonds InvesteringsRijpe STarts (FIRST), supported by additional funding from Health Holland. Pleas find the full press release attached!
July 7th, 2020 – After two years of working on what has been purely a scientific endeavour, Coen Maas, Steven de Maat, Kristof Vercruysse and Marc van Moorsel have now officially founded TargED Biopharmaceuticals B.V. as UMC Utrecht spin-off. Why this name? Because TargED actually… Read More »FOUNDED